Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001558370-25-004869
Filing Date
2025-04-16
Accepted
2025-04-16 06:02:31
Documents
23
Period of Report
2025-06-11

Document Format Files

Seq Description Document Type Size
1 PRE 14A qure-20250611xpre14a.htm   iXBRL PRE 14A 1957026
2 GRAPHIC qure-20250611xpre14a_a001.jpg GRAPHIC 9542
3 GRAPHIC qure-20250611xpre14a_a002.jpg GRAPHIC 2513
4 GRAPHIC qure-20250611xpre14a_a016.jpg GRAPHIC 32945
5 GRAPHIC qure-20250611xpre14a_a017.jpg GRAPHIC 37085
6 GRAPHIC qure-20250611xpre14a_bg001.jpg GRAPHIC 150449
7 GRAPHIC qure-20250611xpre14a_bg002.jpg GRAPHIC 119020
  Complete submission text file 0001558370-25-004869.txt   3776284

Data Files

Seq Description Document Type Size
8 EX-101.SCH qure-20250611.xsd EX-101.SCH 4536
9 EX-101.DEF qure-20250611_def.xml EX-101.DEF 3505
10 EX-101.LAB qure-20250611_lab.xml EX-101.LAB 5187
11 EX-101.PRE qure-20250611_pre.xml EX-101.PRE 4670
25 EXTRACTED XBRL INSTANCE DOCUMENT qure-20250611xpre14a_htm.xml XML 275084
Mailing Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36294 | Film No.: 25841133
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)